Elevated antidrug antibodies against atezolizumab and associated clinical outcomes in advanced non-small-cell lung cancer
Cancer Immunology, Immunotherapy · 2025
DOI: 10.1007/s00262-025-04245-3 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Immunology, Immunotherapy, 2025. Verfasst von Miran Jang und 7 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-Ro, Gangnam-Gu,…. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Antibodies, Monoclonal, Humanized, Antineoplastic Agents. Die Arbeit nennt 19 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: National Research Foundation of Korea [NRF] grants funded by the Korean government [MSIT], Future Medicine 2030 Project of the Samsung Medical Center, National Research Foundation of Korea (NRF) grants funded by the Korean government (MSIT).
Abstract (Originalsprache)
BACKGROUND: Although atezolizumab has demonstrated efficacy in advanced non-small-cell lung cancer (NSCLC), antidrug antibody (ADA) may reduce its effectiveness by lowering drug exposure. We explored the association between ADA levels and clinical outcomes. METHODS: We retrospectively analyzed 86 patients with advanced NSCLC who received atezolizumab monotherapy (1200 mg every 3 weeks) between August 2018 and September 2022 at Samsung Medical Center, Seoul, Korea. Blood samples were collected prior to the first and second doses (baseline and week 3). ADA levels were measured by ELISA and correlated with plasma atezolizumab concentrations and clinical outcomes using Kaplan-Meier estimates and Cox proportional hazards models. RESULTS: All 86 patients received atezolizumab as a second-line or later treatment (second-line, n = 65; third-line, n = 12; ≥ fourth-line, n = 9). Patients (median age [IQR], 67 [61-73] years; 73 [84.9%] male) showed significantly elevated ADA levels three weeks after treatment (median [IQR] 0 [0-0] vs. 530.3 [146.9-3050.5] ng/mL; p < 0.001). Strong ADA levels (≥ 1000 ng/mL) were observed in 32 (37.2%) patients and were associated with shorter PFS (HR = 1.86, 95% CI: 1.15-3.02, p = 0.010) and OS (HR = 1.92, 95% CI: 1.14-3.23, p = 0.013). Furthermore, patients with high ADA levels exhibited lower atezolizumab concentrations and reduced response rates compared to those with low ADA levels. Importantly, high ADA levels independently predicted poor prognosis in a multivariable analysis adjusted for clinical variables. CONCLUSIONS: High ADA levels were linked to lower atezolizumab exposure and worse outcomes. ADA monitoring may help predict prognosis and guide immunotherapy strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-Ro, Gangnam-Gu, Seoul, 06351, Republic of Korea.
- Medical Oncology, CHA Bundang Medical Center, CHA University School of Medicine, 59 Yatap-Ro, Bundang-Gu, Seongnam, 13496, Republic of Korea.
- Department of Radiology and Center for Imaging Science, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-Ro, Gangnam-Gu, Seoul, 06351, Republic of Korea.
- Department of Health Sciences and Technology, Samsung Advanced Institute of Health Sciences and Technology, Sungkyunkwan University, 115, Irwon-Ro, Gangnam-Gu, Seoul, 06355, Republic of Korea.
- Medical Oncology, CHA Bundang Medical Center, CHA University School of Medicine, 59 Yatap-Ro, Bundang-Gu, Seongnam, 13496, Republic of Korea. minidoctor@cha.ac.kr.
- Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, 81 Irwon-Ro, Gangnam-Gu, Seoul, 06351, Republic of Korea. shlee119@skku.edu.
Förderung
- National Research Foundation of Korea [NRF] grants funded by the Korean government [MSIT]
- Future Medicine 2030 Project of the Samsung Medical Center
- National Research Foundation of Korea (NRF) grants funded by the Korean government (MSIT)
- Bio&Medical Technology Development Program of the National Research Foundation (NRF) funded by the Korean government (MSIT)
- National Research Foundation of Korea (NRF) grant funded by the Korea government
- Korea Health Technology R&D Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Ko…
- grant of Korean ARPA-H Project through the Korea Health Industry Development Institute (KHIDI), funded by the Ministry of Health & Welfare, Republic of Korea
- grant of the Korea-US Collaborative Research Fund(KUCRF), funded by the Ministry of Science and ICT and Ministry of Health & Welfare, Republic of Korea
Zitieren
APA
Jang, M., Kim, C., Kong, S. J., Yang, H., Lee, W. S., Lee, H. Y., Chon, H. J., & Lee, S. H. (2025). Elevated antidrug antibodies against atezolizumab and associated clinical outcomes in advanced non-small-cell lung cancer. Cancer Immunology, Immunotherapy. https://doi.org/10.1007/s00262-025-04245-3
Vancouver
Jang M, Kim C, Kong SJ, Yang H, Lee WS, Lee HY, et al. Elevated antidrug antibodies against atezolizumab and associated clinical outcomes in advanced non-small-cell lung cancer. Cancer Immunology, Immunotherapy. 2025. doi:10.1007/s00262-025-04245-3
BibTeX
@article{Jang2025,
author = {Jang, Miran and Kim, Chan and Kong, So Jung and Yang, Hannah and Lee, Won Suk and Lee, Ho Yun and Chon, Hong Jae and Lee, Se-Hoon},
title = {Elevated antidrug antibodies against atezolizumab and associated clinical outcomes in advanced non-small-cell lung cancer},
journal = {Cancer Immunology, Immunotherapy},
year = {2025},
doi = {10.1007/s00262-025-04245-3}
}
EUVIMED